Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interestingly enough, Toutain is not mentioned in the proxy by name or by job title. He certainly wasn't listed as receiving any share options that were reported.
He has a much better pay package at his new gig. He has a big pay raise, stock options etc. Congratulations to him on his step up.
Update by MayoMobile:
https://www.sotcanalytics.com/update-compendium-2024#h.874e6qgoo0o6
Good stuff! : )
What? You have never engaged in best case possibilities thinking?
He said it was if. Just like saying if Rett was approved we would have a $30 share price. If didn't happen. But if it had, $30 sp was a real possibility.
Same is the case for AD in the EU. If it is approved the share price could be $35 or more.
There sure are enough post about the worst case possibilities, I don't see a lot of push back on those.
In either case, these are discussions of the possible rage of outcomes. If enough things break positive for Anavex, that $1248 sp is possible. If enough things break badly for Anavex the pennies are possible. The real outcome remains to be seen.
What is posted on this board has little to do with the ultimate outcome, pumping or bashing.
Trial results are all that matters, the rest is entertainment.
Wow. George Orwell would be proud of your post.
Calling George "the perfect FUDster" and then referring to yourself as "us truth tellers".
PDSB with a success P2 trial
It's time to screw P3
PDS Biotech appoints Stephan Toutain as COO
PDSB TOP INSTITUTION SHAREHOLDER
BLACK ROCK
In connection with his appointment, PDS Biotech granted Toutain a nonstatutory stock option to purchase 200,000 shares of common stock at an exercise price of $3.61 per share, the closing price on May 1, 2024. The option will vest over four years, contingent upon continued employment.
Got the picture ?
Of course I deny it. Missling has his flaws but the stock is where it is right now primarily due to short manipulation. It was manipulated to 30 based on nothing and now it’s been manipulated down to 3 despite best ever controlled AD trial results and an imminent EMA application.
That is not true at all.
I originally bought AVXL stock at 18 cents per share prior to the one for four reverse split.
That is the truth, the whole truth and nothing but the truth, under the leadership of Christopher U. Missling, PhD, MS, MBA.
GOD bless,
You want the truth? Here’s the truth, the whole truth, and nothing but the truth: under the leadership of Christopher U. Missling, PhD, MS, MBA, BSr, shareholder value has been decimated. Hard as he may try, even ignatiusrielly35 cannot deny that fact.
That's a pretty lame excuse. Read the first sentence and the last paragraph and tell me there isn't any fairy tale pumping.
What part of the word "if" did you not understand in his post.
Falconer set the the conditions and then followed the consequences if the conditions are met. That is what "if" means.
I wonder what the cost is to enforce an NDA?
I am reminded of the saying:
Lay down with dogs expect fleas.
George probably wouldn’t recognize the
“truth” let alone define “proof” or truth
if it smacked him upside the head.
Exactly that is why you are the perfect FUDster. The rest if us truth tellers try not act blind. Is that why you are here...waiting for the Anavex blindness trial...
This golden parachute proposal is interesting. A proposal made by a shareholder/s. Inside knowledge of something brewing or just someone that doesn’t want to get bent over?
I wonder what Toutain’s package was. Anyone?
Yes, the FUDsterss do not like the truth and they get in a panic whenever the read the truth.
Good luck and GOD bless,
Nice work, George. Your post set off a virtual panic amongst the Fudsters. Look how they flooded the board in response. LOL
I believe that Anavex may submit a Marketing Authorisation Application to the European Medicine Agency, EMA for blarcamesine related to the treatment of Alzheimer’s disease by or before summer 2024 and possibly obtain EMA approval to start selling blarcamesine in the EU by or before the end of 2024.
Good luck and GOD bless,
Pumper Jesse/Mobile came up with Q&A, he is answering his own questions, pathetic way to pump this garbage.
Totally agree. Time to clean house.
Whatever this useless BOD recommends, I vote the opposite. For them to sit idly by while the wheels came off the wagon is inexcusable. A lot of needless damage to this company’s credibility has occurred while they sat on their thumbs.
It really is time to clean house and hold the BOD members responsible. SH have a right to be angry with what has transpired this past year.
Noone should be getting options and bonuses for this past year—it is disgraceful and shameful.
Times article - Genetic trait that virtually ‘guarantees’ Alzheimer’s identified
Researchers have identified a genetic trait that makes it virtually “guaranteed” a person will get Alzheimer’s in a discovery that may pave the way to better targeted treatments and earlier diagnoses.
A study found that having two copies of a specific gene makes it almost inevitable that a person will eventually develop symptoms.
Experts said the discovery may help the development of targeted treatments and could enable genetic testing and earlier interventions.
More than 900,000 people have dementia in the UK, the majority of whom have Alzheimer’s. There is no cure for the disease, although treatments have been found to slow its progress.
In the study, researchers in Barcelona found that 95 per cent of people over 65 with two copies of the APOE4 gene variant developed signs of the disease. About one in four people in the UK have one copy of this gene, while one in fifty — equivalent to more than a million people — have two.
“This gene has been known for over 30 years and it was known to be associated with a higher risk of developing Alzheimer’s disease,” said Dr Juan Fortea, director of the memory unit of the neurology service at Sant Pau Research Institute, and lead author of the study.
“But now we know that virtually all individuals with this duplicated gene develop Alzheimer’s biology.”
The researchers said their findings effectively amounted to the discovery of a new genetic form of the disease, because the presence of both genes was such a useful predictor for the condition.
The findings, published in the journal Nature Medicine, are based on data from more than 10,000 people and more than 3,000 brain donors.
Siân Gregory, the research manager at Alzheimer’s Society, said: “I think it’s definitely a breakthrough for the field in terms of how we think about the causes of Alzheimer’s disease.” She said it would make it easier to predict when symptoms might start and enable doctors to give people more advice at diagnosis.
Dr Richard Oakley, Alzheimer’s Society’s associate director of research and innovation, said: “Understanding the causes of the disease in greater detail is vital and can unlock new ways of diagnosing, treating and caring for people affected by Alzheimer’s disease in the future.
“The insights from the study suggest that in the future it could be important to take into account a person’s genetics when planning how to reduce their risk of developing Alzheimer’s disease, or when considering their treatment if they already have the disease.”
Previous studies have shown that having at least one APOE4 gene variant almost triples the risk of getting the disease, while having two copies increases the risk by up to twelvefold.
In the latest research, a majority of people with two copies of APOE4 showed some signs of the disease by the age of 55. By age 65, 95 per cent of them had abnormal levels of a protein known as amyloid in the fluid that surrounds the brain and spinal cord, which is a key sign of Alzheimer’s disease.
Professor Tara Spires-Jones, president of the British Neuroscience Association and group leader at the UK Dementia Research Institute at the University of Edinburgh, said: “This study adds compelling data to suggest that people with two copies of this gene are almost guaranteed to develop Alzheimer’s if they live long enough and that they will develop Alzheimer’s earlier than people without this gene.”
Dr Víctor Montal, a researcher who studies the molecular structure of the APOE gene at the Barcelona Supercomputing Centre, added that the findings could be used to monitor people with this gene from an early age for preventive interventions. Drugs such as donanemab and lecanemab have been shown to slow the progression of the condition in clinical trials.
https://www.thetimes.co.uk/article/alzheimers-disease-genetic-cause-treatment-jgwwtcccn
Amazing, right? Wild imaginations spinning out of control.
Who’s voting “FOR” on Golden Parachute Payments to prevent excessive generous payouts?
Of course, BOD recommends for everyone to vote “AGAINST” but battered shareholders should unite and vote for this proposal to pass.
Yep, the BSers and their enablers are equally at fault on this board.
OMG. And this is how the BS snowballs.
Wow. Really turning up the pump machine today!
Thankfully, nobody believe you anymore.
Because BMS Wants to Own the Schizophrenia SOC
George:
Please STFU about how many companies are interested in buying/partnering. So far, it’s zero for 9 years.
Wait until you hear about the results from the Anavex 3-71 trial for the treatment of schizophrenia.
That will answer the question as to why BMS is interested in partnering with or buying Anavex Life Sciences.
Good luck and GOD bless,
I believe that George may have made this up.
George, I love your research but why would BMS want to partner or buy AVXL when they just spent $12B on Karuna Therapeutics. That could be seen as a huge overlap considering it could/would cost them about the same if they went after Anavex.
Bristol Myers Squibb is extremely interested in partnering with or buying Anavex Life Sciences.
Good luck and GOD bless,
I was told the same thing from my imaginary friend.
When I recently invested in the company it wasn't in the belief that they had the cure to AD, RETT's, etc. I believe that these, and other diseases are rather like cancer, you keep coming up with new treatment that improves on the old, but no magic bullet is coming along that simply cures everyone. In my opinion we're making improvement in the treatment of these and other diseases, not a cure, but an improvement that could become a part of the SOC for a significantly long time and should bring in multi-billions annually once they're accepted.
I don't know if the company will exist after multiple approvals and billions in sales, or be bought out, but either way, investors should be well rewarded. The key is getting that first approval.
Gary
Perhaps he then should also turn his attention to Remi Barbier at SAVA.
when TBSD BS or george post shiiiit SP DROP
They are BLACK ROCK favor shiiit
Mr. Steiner was largely responsible for Dr. Ma PhD from becoming an independent Chairperson of the Board of Directors of AVXL.
https://www.sec.gov/files/corpfin/no-action/14a-8/steinerchevedden042023-14a8-incoming.pdf
It is somewhat common practice for the Chairman or Chairperson of the BOD to be an independent director.
Good luck and GOD bless,
Should have read as “I have no problem.”
Yeah, I have problem with what he is proposing. But you are right, he seems to be more of a good samaritan rather than a shareholder activist trying to improve his own investment, e.g., a Carl Icahn type.
Maybe. Who knows? If they are in fact unhappy they have not attempted any action to try to change anything, as far as we know.
I am expecting that Anavex 3-71 will prove to be very safe, very well tolerated and very efficacious very soon for the treatment of schizophrenia.
Good luck and GOD bless,
Dr. Christopher U. Missling MS PhD MBA is the beneficial owner of more AVXL shares than either Blackjack or Vanguard.
Good luck and GOD bless,
BLACK ROCK LOVE TBSD
FAIL ALL TRIALS
NO NDA
NO PEER REVIEW
NO APPROVAL
NO COMMERCIAL
EVENTUALLY BLACK ROCK CAN GET AVXL VERY VERY CHEAP
Go back to your toilet cleaning job. It suits you better.
No one is talking to this POS, there is no value in this sugar pill. This is going down to penny land and Misleading will get fired soon, very soon, it is around the corner.
I'm sure he means well, but I also see it as just a rich dude using populism for attention.
I believe that there are currently negotiations going on with big pharmaceuticals to either partner with or buy out Anavex Life Sciences.
Good luck and GOD bless,
Followers
|
1066
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
458440
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |